Developmental basis for filamin-A-associated myxomatous mitral valve disease

Kimberly Sauls, Annemarieke De Vlaming, Brett S. Harris, Katherine Williams, Andy Wessels, Robert A. Levine, Susan A. Slaugenhaupt, Richard L. Goodwin, Luigi Michele Pavone, Jean Merot, Jean Jacques Schott, Thierry Le Tourneau, Thomas Dix, Sean Jesinkey, Yuanyi Feng, Christopher Walsh, Bin Zhou, Scott Baldwin, Roger R. Markwald, Russell A. Norris

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

AimsWe hypothesized that the structure and function of the mature valves is largely dependent upon how these tissues are built during development, and defects in how the valves are built can lead to the pathological progression of a disease phenotype. Thus, we sought to uncover potential developmental origins and mechanistic underpinnings causal to myxomatous mitral valve disease. We focus on how filamin-A, a cytoskeletal binding protein with strong links to human myxomatous valve disease, can function as a regulatory interface to control proper mitral valve development.Methods and resultsFilamin-A-deficient mice exhibit abnormally enlarged mitral valves during foetal life, which progresses to a myxomatous phenotype by 2 months of age. Through expression studies, in silico modelling, 3D morphometry, biochemical studies, and 3D matrix assays, we demonstrate that the inception of the valve disease occurs during foetal life and can be attributed, in part, to a deficiency of interstitial cells to efficiently organize the extracellular matrix (ECM). This ECM organization during foetal valve gestation is due, in part, to molecular interactions between filamin-A, serotonin, and the cross-linking enzyme, transglutaminase-2 (TG2). Pharmacological and genetic perturbations that inhibit serotonin-TG2-filamin-A interactions lead to impaired ECM remodelling and engender progression to a myxomatous valve phenotype.ConclusionsThese findings illustrate a molecular mechanism by which valve interstitial cells, through a serotonin, TG, and filamin-A pathway, regulate matrix organization during foetal valve development. Additionally, these data indicate that disrupting key regulatory interactions during valve development can set the stage for the generation of postnatal myxomatous valve disease.

Original languageEnglish (US)
Pages (from-to)109-119
Number of pages11
JournalCardiovascular Research
Volume96
Issue number1
DOIs
StatePublished - Oct 1 2012

Fingerprint

Filamins
Mitral Valve
Extracellular Matrix
Serotonin
Phenotype
Cytoskeletal Proteins
Fetal Development
Computer Simulation
Disease Progression
Carrier Proteins
Pharmacology
Pregnancy
Enzymes

Keywords

  • Filamin-A
  • Myxomatous valve disease
  • Serotonin
  • Transglutaminase-2
  • Valve maturation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Sauls, K., De Vlaming, A., Harris, B. S., Williams, K., Wessels, A., Levine, R. A., ... Norris, R. A. (2012). Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovascular Research, 96(1), 109-119. https://doi.org/10.1093/cvr/cvs238

Developmental basis for filamin-A-associated myxomatous mitral valve disease. / Sauls, Kimberly; De Vlaming, Annemarieke; Harris, Brett S.; Williams, Katherine; Wessels, Andy; Levine, Robert A.; Slaugenhaupt, Susan A.; Goodwin, Richard L.; Pavone, Luigi Michele; Merot, Jean; Schott, Jean Jacques; Le Tourneau, Thierry; Dix, Thomas; Jesinkey, Sean; Feng, Yuanyi; Walsh, Christopher; Zhou, Bin; Baldwin, Scott; Markwald, Roger R.; Norris, Russell A.

In: Cardiovascular Research, Vol. 96, No. 1, 01.10.2012, p. 109-119.

Research output: Contribution to journalArticle

Sauls, K, De Vlaming, A, Harris, BS, Williams, K, Wessels, A, Levine, RA, Slaugenhaupt, SA, Goodwin, RL, Pavone, LM, Merot, J, Schott, JJ, Le Tourneau, T, Dix, T, Jesinkey, S, Feng, Y, Walsh, C, Zhou, B, Baldwin, S, Markwald, RR & Norris, RA 2012, 'Developmental basis for filamin-A-associated myxomatous mitral valve disease', Cardiovascular Research, vol. 96, no. 1, pp. 109-119. https://doi.org/10.1093/cvr/cvs238
Sauls K, De Vlaming A, Harris BS, Williams K, Wessels A, Levine RA et al. Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovascular Research. 2012 Oct 1;96(1):109-119. https://doi.org/10.1093/cvr/cvs238
Sauls, Kimberly ; De Vlaming, Annemarieke ; Harris, Brett S. ; Williams, Katherine ; Wessels, Andy ; Levine, Robert A. ; Slaugenhaupt, Susan A. ; Goodwin, Richard L. ; Pavone, Luigi Michele ; Merot, Jean ; Schott, Jean Jacques ; Le Tourneau, Thierry ; Dix, Thomas ; Jesinkey, Sean ; Feng, Yuanyi ; Walsh, Christopher ; Zhou, Bin ; Baldwin, Scott ; Markwald, Roger R. ; Norris, Russell A. / Developmental basis for filamin-A-associated myxomatous mitral valve disease. In: Cardiovascular Research. 2012 ; Vol. 96, No. 1. pp. 109-119.
@article{c4770f87ccee4cb29b98c1e3d8ca0686,
title = "Developmental basis for filamin-A-associated myxomatous mitral valve disease",
abstract = "AimsWe hypothesized that the structure and function of the mature valves is largely dependent upon how these tissues are built during development, and defects in how the valves are built can lead to the pathological progression of a disease phenotype. Thus, we sought to uncover potential developmental origins and mechanistic underpinnings causal to myxomatous mitral valve disease. We focus on how filamin-A, a cytoskeletal binding protein with strong links to human myxomatous valve disease, can function as a regulatory interface to control proper mitral valve development.Methods and resultsFilamin-A-deficient mice exhibit abnormally enlarged mitral valves during foetal life, which progresses to a myxomatous phenotype by 2 months of age. Through expression studies, in silico modelling, 3D morphometry, biochemical studies, and 3D matrix assays, we demonstrate that the inception of the valve disease occurs during foetal life and can be attributed, in part, to a deficiency of interstitial cells to efficiently organize the extracellular matrix (ECM). This ECM organization during foetal valve gestation is due, in part, to molecular interactions between filamin-A, serotonin, and the cross-linking enzyme, transglutaminase-2 (TG2). Pharmacological and genetic perturbations that inhibit serotonin-TG2-filamin-A interactions lead to impaired ECM remodelling and engender progression to a myxomatous valve phenotype.ConclusionsThese findings illustrate a molecular mechanism by which valve interstitial cells, through a serotonin, TG, and filamin-A pathway, regulate matrix organization during foetal valve development. Additionally, these data indicate that disrupting key regulatory interactions during valve development can set the stage for the generation of postnatal myxomatous valve disease.",
keywords = "Filamin-A, Myxomatous valve disease, Serotonin, Transglutaminase-2, Valve maturation",
author = "Kimberly Sauls and {De Vlaming}, Annemarieke and Harris, {Brett S.} and Katherine Williams and Andy Wessels and Levine, {Robert A.} and Slaugenhaupt, {Susan A.} and Goodwin, {Richard L.} and Pavone, {Luigi Michele} and Jean Merot and Schott, {Jean Jacques} and {Le Tourneau}, Thierry and Thomas Dix and Sean Jesinkey and Yuanyi Feng and Christopher Walsh and Bin Zhou and Scott Baldwin and Markwald, {Roger R.} and Norris, {Russell A.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1093/cvr/cvs238",
language = "English (US)",
volume = "96",
pages = "109--119",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Developmental basis for filamin-A-associated myxomatous mitral valve disease

AU - Sauls, Kimberly

AU - De Vlaming, Annemarieke

AU - Harris, Brett S.

AU - Williams, Katherine

AU - Wessels, Andy

AU - Levine, Robert A.

AU - Slaugenhaupt, Susan A.

AU - Goodwin, Richard L.

AU - Pavone, Luigi Michele

AU - Merot, Jean

AU - Schott, Jean Jacques

AU - Le Tourneau, Thierry

AU - Dix, Thomas

AU - Jesinkey, Sean

AU - Feng, Yuanyi

AU - Walsh, Christopher

AU - Zhou, Bin

AU - Baldwin, Scott

AU - Markwald, Roger R.

AU - Norris, Russell A.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - AimsWe hypothesized that the structure and function of the mature valves is largely dependent upon how these tissues are built during development, and defects in how the valves are built can lead to the pathological progression of a disease phenotype. Thus, we sought to uncover potential developmental origins and mechanistic underpinnings causal to myxomatous mitral valve disease. We focus on how filamin-A, a cytoskeletal binding protein with strong links to human myxomatous valve disease, can function as a regulatory interface to control proper mitral valve development.Methods and resultsFilamin-A-deficient mice exhibit abnormally enlarged mitral valves during foetal life, which progresses to a myxomatous phenotype by 2 months of age. Through expression studies, in silico modelling, 3D morphometry, biochemical studies, and 3D matrix assays, we demonstrate that the inception of the valve disease occurs during foetal life and can be attributed, in part, to a deficiency of interstitial cells to efficiently organize the extracellular matrix (ECM). This ECM organization during foetal valve gestation is due, in part, to molecular interactions between filamin-A, serotonin, and the cross-linking enzyme, transglutaminase-2 (TG2). Pharmacological and genetic perturbations that inhibit serotonin-TG2-filamin-A interactions lead to impaired ECM remodelling and engender progression to a myxomatous valve phenotype.ConclusionsThese findings illustrate a molecular mechanism by which valve interstitial cells, through a serotonin, TG, and filamin-A pathway, regulate matrix organization during foetal valve development. Additionally, these data indicate that disrupting key regulatory interactions during valve development can set the stage for the generation of postnatal myxomatous valve disease.

AB - AimsWe hypothesized that the structure and function of the mature valves is largely dependent upon how these tissues are built during development, and defects in how the valves are built can lead to the pathological progression of a disease phenotype. Thus, we sought to uncover potential developmental origins and mechanistic underpinnings causal to myxomatous mitral valve disease. We focus on how filamin-A, a cytoskeletal binding protein with strong links to human myxomatous valve disease, can function as a regulatory interface to control proper mitral valve development.Methods and resultsFilamin-A-deficient mice exhibit abnormally enlarged mitral valves during foetal life, which progresses to a myxomatous phenotype by 2 months of age. Through expression studies, in silico modelling, 3D morphometry, biochemical studies, and 3D matrix assays, we demonstrate that the inception of the valve disease occurs during foetal life and can be attributed, in part, to a deficiency of interstitial cells to efficiently organize the extracellular matrix (ECM). This ECM organization during foetal valve gestation is due, in part, to molecular interactions between filamin-A, serotonin, and the cross-linking enzyme, transglutaminase-2 (TG2). Pharmacological and genetic perturbations that inhibit serotonin-TG2-filamin-A interactions lead to impaired ECM remodelling and engender progression to a myxomatous valve phenotype.ConclusionsThese findings illustrate a molecular mechanism by which valve interstitial cells, through a serotonin, TG, and filamin-A pathway, regulate matrix organization during foetal valve development. Additionally, these data indicate that disrupting key regulatory interactions during valve development can set the stage for the generation of postnatal myxomatous valve disease.

KW - Filamin-A

KW - Myxomatous valve disease

KW - Serotonin

KW - Transglutaminase-2

KW - Valve maturation

UR - http://www.scopus.com/inward/record.url?scp=84866659103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866659103&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvs238

DO - 10.1093/cvr/cvs238

M3 - Article

C2 - 22843703

AN - SCOPUS:84866659103

VL - 96

SP - 109

EP - 119

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -